Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 3

NCT06255392

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Inv…

This study develops a new therapeutic approach for HER2-negative advanced breast cancer patients without precise treatment targets. The trial aims at extending…

China200 participantsStarted 2024-06-12

Treatment: Fluzoparib, Apatinib Mesylate

All recent trials (5 shown)

SuspendedPhase 2

NCT05656131

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advance…

This study is planned to include 80 patients with HRD positive HER2-negative advanced breast cancer to receive fluzoparib alone or fluzoparib combined with camr…

China80 participantsStarted 2022-11-23

Treatment: Fluzoparib, Fluzoparib+Camrelizumab

Active — Not RecruitingPhase 3

NCT07371910

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

This is a Phase III clinical trial for patients with a specific type of advanced breast cancer that is HER2-negative and has a biomarker called "Homologous Reco…

China200 participantsStarted 2024-06-12

Treatment: Chemotherapy/ADC Regimen, Fluorizoparib

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Inv…

All recent trials (5 shown)

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advance…

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Inv…

All recent trials (5 shown)

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advance…

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer